Literature DB >> 18484589

Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma.

Maria F Serrano1, Matthew Katz, Yan Yan, Adam S Kibel, Peter A Humphrey.   

Abstract

BACKGROUND: The prognostic value of Fuhrman nuclear grade for patients with renal cell carcinoma has been well-characterized. However, to the authors' knowledge, the prognostic significance of the amount of high-grade renal cell carcinoma has not been previously analyzed.
METHODS: The authors identified 898 consecutive renal cell carcinoma cases treated with nephrectomy between 1989 and 2003. Histopathologic features that were captured based on re-review of all slides included histologic type, pathologic stage, conventional Fuhrman grade, and percentage of Fuhrman grade 3 and 4 carcinoma, as ascertained by visual inspection of histologic slides. The clinical endpoints were metastasis-free survival, cancer-specific survival, and overall survival.
RESULTS: Kaplan-Meier analysis demonstrated that both conventional Fuhrman grading and the percentage of Fuhrman grade 3 and 4 carcinoma were highly correlated with all 3 measures of patient survival (P < .0001). The creation of 3 categories of the percentage of Fuhrman grade 3 and 4 carcinoma (0%, 1-50%, and 51-100%) generated distinctly separate survival curves. On Cox proportional hazards multivariate analysis, TNM stage, tumor size, and the percentage of Fuhrman grade 3 and 4 carcinoma were all found to be significantly associated with all 3 types of patient survival (all P values <.05).
CONCLUSIONS: The determination of the percentage of renal cell carcinoma that is 0%, 1% to 50%, or 51% to 100% high Fuhrman grade 3 and 4 is a simple and powerful measurement of patient outcome after surgery that provides additional prognostic information beyond stage, tumor size, and conventional Fuhrman grade. This prognostic information could be useful in the stratification of patients into prognostic groups for the development of more individualized follow-upschedules and for enrollment into clinical trials. (c) 2008 American Cancer Society

Entities:  

Mesh:

Year:  2008        PMID: 18484589     DOI: 10.1002/cncr.23574

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Jesús M Cortés; José I López
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

Review 2.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

Review 3.  Tissue biomarkers in renal cell carcinoma: issues and solutions.

Authors:  Arianna Di Napoli; Sabina Signoretti
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

Review 4.  Nephron-sparing surgery for multifocal and hereditary renal tumors.

Authors:  Adam R Metwalli; William M Linehan
Journal:  Curr Opin Urol       Date:  2014-09       Impact factor: 2.309

5.  Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.

Authors:  Joshua I Warrick; Alex Tsodikov; Lakshmi P Kunju; Arul M Chinnaiyan; Ganesh S Palapattu; Todd M Morgan; Ajjai Alva; Scott Tomlins; Angela Wu; Jeffrey S Montgomery; Khaled S Hafez; J Stuart Wolf; Alon Z Weizer; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-02-20       Impact factor: 3.466

6.  A MUCINs expression signature impacts overall survival in patients with clear cell renal cell carcinoma.

Authors:  Hui Meng; Xuewen Jiang; Huangwei Huang; Neng Shen; Changsheng Guo; Chunxiao Yu; Gang Yin; Yu Wang
Journal:  Cancer Med       Date:  2021-07-29       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.